Comparable Pharmacokinetics (PK) of Two Delayed Release Formulations of Oral Mesalamine

Review article: 5‐aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5‐aminosalicylate to the colonic mucosa

“…As most PK studies use only small sample sizes, making definitive conclusions is difficult. Nevertheless, in a number of studies, 5‐ASA formulations have been compared on the basis of plasma PK data 62, 64–68 . While similar 5‐ASA plasma PK profiles may potentially predict similar safety profiles, conclusions regarding efficacy, dosing schedules or colonic release characteristics of 5‐ASA should be considered with caution.…”

Review article: evolving concepts in treatment and disease modification in ulcerative colitis

“…Aminosalicylates, which include mesalazine, sulphasalazine, olsalazine and balsalazide, are the standard treatment for the induction and maintenance of remission in mild‐to‐moderate UC patients because of their efficacy and safety profiles. Oral 5‐ASAs used to treat UC are available in a range of formulations with different release characteristics (Table 1), but have comparable pharmacokinetics in terms of systemic absorption, urinary excretion and faecal excretion of 5‐ASA 4, 5 …”

Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials

“…Research results have demonstrated that oral delayedrelease mesalamine can be administered once daily [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. However, there is no meta-analysis to evaluate the pooled efficacy and safety of a once-daily regime of oral mesalamine.…”